Assessing outcomes in prostate cancer clinical trials: A twenty-first century tower of babel Academic Article uri icon

Overview

MeSH Major

  • Clinical Trials, Phase II as Topic
  • Disease-Free Survival
  • Prostatic Neoplasms
  • Research Design

abstract

  • Outcome assessment policies are highly variable in phase 2 studies of castration-resistant prostate cancer patients, despite published guidelines designed to standardize authentication of disease progression. The estimated error in PFS can exceed 6 weeks per cycle, exclusively because of variations in the assessment schedules. Comparisons of PFS times from different studies must be made with circumspection.

publication date

  • September 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2708077

Digital Object Identifier (DOI)

  • 10.1002/cncr.23719

PubMed ID

  • 18661513

Additional Document Info

start page

  • 966

end page

  • 74

volume

  • 113

number

  • 5